PLos One:绝经后乳腺癌患者运动能力下降的影响因素

2017-03-19 MedSci MedSci原创

乳腺癌治疗包括根治性手术,其在妇女生命的第7至第8个十年期间进行。标准身体康复程序为这些妇女提供了减轻上肢和躯干特定功能上的缺陷。目前,很少有关于恢复整体功能以及减少跌倒风险的治疗方案相关研究。近期,一项发表在PLos One上的研究旨在评估绝经后、手术后乳腺癌幸存者中自我报告的跌倒、个体功能能力以及减少跌倒风险的潜在相互关系。此项研究共招募了102名女性(年龄65-79岁;平均年龄70.2岁),

乳腺癌治疗包括根治性手术,其在妇女生命的第7至第8个十年期间进行。标准身体康复程序为这些妇女提供了减轻上肢和躯干特定功能上的缺陷。目前,很少有关于恢复整体功能以及减少跌倒风险的治疗方案相关研究。


近期,一项发表在PLos One上的研究旨在评估绝经后、手术后乳腺癌幸存者中自我报告的跌倒、个体功能能力以及减少跌倒风险的潜在相互关系。

此项研究共招募了102名女性(年龄65-79岁;平均年龄70.2岁),均为乳腺癌术后的幸存者。受试者按年龄分为三组:第1组(65-69岁);第2组(70-74岁)和第3 组(75-79岁)。使用八英尺up&go测试(8UG)、椅子站立测试(CST)和2分钟步行测试(2ST)评估单独的功能能力。应用Tinetti POMA测试来评估步态和平衡障碍。通过问卷评估自我报告过去一年的跌倒情况。

此项研究结果显示:个体有氧耐力评价(2ST)显示所有年龄亚组中的平均得分与参考值相比出现明显缺乏。缺陷范围从4.86到15.90步;年纪最大的亚组表现出最大的缺陷。有氧耐力测试结果显着影响了最老龄组中个体跌倒风险的最终评估。对最近一年内跌倒数目的分析显示,有43.67%的受访者是这类事件的受害者。

此项研究结果表明:在超过75岁的乳腺癌幸存者中,个人暴露于跌倒风险更多地依赖于个体的有氧耐力而不是身体下部的总体强度。

原始出处:
Zak M, Biskup M, et al. Identifying predictive motor factors for falls in post-menopausal breast cancer survivors. PLoS One. 2017 Mar 17;12(3):e0173970. doi: 10.1371/journal.pone.0173970. eCollection 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
    2017-03-21 zxxiang
  7. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
    2017-03-20 医艺依意

    说白了,肺部基础毛病

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1789904, encodeId=aab71e89904db, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jul 14 23:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257085, encodeId=8eaa125e085ae, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465532, encodeId=31d8146553264, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499977, encodeId=09f614999e777, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571027, encodeId=844215e10277c, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631536, encodeId=0ca61631536c5, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Mar 21 04:54:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181319, encodeId=a4da18131919, content=说白了,肺部基础毛病, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Mon Mar 20 07:49:42 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181148, encodeId=bb1a18114829, content=学习起来了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib0kbzef1jKfxVxKKxoGdVMdMe54JuaABgJlOdkfVdUkxEReXZyZ0PMHhxlzMkiciaPAp2gJsoIbGKtA/0, createdBy=a2d51960177, createdName=komasun, createdTime=Sun Mar 19 14:04:02 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
    2017-03-19 komasun

    学习起来了,学习

    0

相关资讯

盘点:近期乳腺癌治疗研究成果一览

乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势;我国乳腺癌的发病率也逐年上升,每年有近20万女性被诊断出乳腺癌。本文梅斯医学小编近期乳腺癌相关研究进行盘点,与大家分享学习。【1】Nature Medicine:20% 乳腺癌患者中可以 PARP 抑制剂治疗治疗中获益 来自 Wellcome Trust Sanger 研究所的研究人员及其

Nat Med:20% 乳腺癌患者中可以 PARP 抑制剂治疗治疗中获益

来自 Wellcome Trust Sanger 研究所的研究人员及其合作者已经发现,更多数量的乳腺癌在遗传上类似于具有错误的 BRCA1 或 BRCA2 基因的罕见病例。今天(3 月 13 日)在 Nature Medicine 上发表的结果揭示了高达 20%的妇女接受 PARP 抑制剂治疗的可能性,PARP 抑制剂是一种以前仅被认为对具有遗传性 BRCA1 或 BRCA2 突变的妇女有效的药物

JCO:二甲双胍可以显著改善HER2阳性早期乳腺癌合并糖尿病患者的预后

既往研究显示,糖尿病合并乳腺癌患者使用二甲双胍,可以改善患者生存结局。 近日,JCO杂志在线发文,纳入国际多中心大样本III期辅助治疗随机对照研究ALTTO的病例,探索性分析HER2阳性合并糖尿病的早期乳腺癌患者,二甲双胍治疗是否影响患者的复发和死亡风险。结果显示,在HER2阳性HR阳性合并糖尿病的早期乳腺癌患者中,服用二甲双胍治疗,对比未服药患者,复发和死亡风险更低。

Cell Rep:科学家发现乳癌化疗后复发的可能机制

癌症治疗的预后评估中,是否复发也是一项很重要的观察,让接受过治疗的癌症患者定期追踪,是不容忽视的环节。《Cell Reports》日前刊登美国约翰.霍普金斯大学(Johns Hopkins University)的最新发表,研究团队发现乳癌干细胞(breast cancer stem cells)于化疗(chemotherapy)后再度生长相关的生化途径,而癌症干细胞的再次生长即为癌症治疗产生抗药

Clin Cancer Res:Palbociclib可阻止早期乳腺癌细胞增殖

Palbociclib被欧美批准用于联合来曲唑或氟维司群治疗激素受体阳性(HR+)、人表皮生长因子2阴性(HER2-)进展期或晚期乳腺癌。而对于HR+/HER2早期乳腺癌多项研究证实palbociclib具有抗增殖作用,并探索在早期乳腺癌中生物标志物的改变。

JAMA Oncol:怀孕会增加乳腺癌患者的死亡风险吗?

2016年美国约有247000名女性诊断为乳腺癌,其中包括26392名小于45岁的女性。近年来,首次分娩产妇年龄增长了5岁,超过35岁的产妇比例也增加。由于生育年龄的推迟,怀孕期间患乳腺癌的妇女(或接受治疗后计划怀孕的乳腺癌患者)比例增加。妊娠期(或分娩后1年)诊断为乳腺癌的患者均有一些临床病理特点,如肿瘤分级高,ER(雌激素受体),PR(孕激素受体)低表达。然而,怀孕是否会影响生存仍是一个争论的